Correlates of uptake of optimal doses of sulfadoxine-pyrimethamine for prevention of malaria during pregnancy in East-Central Uganda.
Adolescent
Adult
Antimalarials
/ administration & dosage
Dose-Response Relationship, Drug
Drug Combinations
Female
Humans
Malaria
/ prevention & control
Middle Aged
Patient Acceptance of Health Care
/ statistics & numerical data
Pregnancy
Pyrimethamine
/ administration & dosage
Socioeconomic Factors
Sulfadoxine
/ administration & dosage
Uganda
Young Adult
Demographic and health survey
Intermittent preventive treatment during pregnancy
Malaria
Uganda
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
23
03
2020
accepted:
07
04
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
18
11
2020
Statut:
epublish
Résumé
In 2012, the World Health Organization recommended that pregnant women in malaria-endemic countries complete at least three (optimal) doses of intermittent preventive treatment (IPTp) using sulfadoxine-pyrimethamine (SP) to prevent malaria and related adverse events during pregnancy. Uganda adopted this recommendation, but uptake remains low in East-Central and information to explain this low uptake remains scanty. This analysis determined correlates of uptake of optimal doses of IPTp-SP in East-Central Uganda. This was a secondary analysis of the 2016 Uganda Demographic Health Survey data on 579 women (15-49 years) who attended at least one antenatal care (ANC) visit and had a live birth within 2 years preceding the survey. Uptake of IPTp-SP was defined as optimal if a woman received at least three doses; partial if they received 1-2 doses or none if they received no dose. Multivariate analysis using multinomial logistic regression was used to determine correlates of IPTp-SP uptake. Overall, 22.3% of women received optimal doses of IPTp-SP, 48.2% partial and 29.5% none. Attending ANC at a lower-level health centre relative to a hospital was associated with reduced likelihood of receiving optimal doses of IPTp-SP. Belonging to other religious faiths relative to Catholic, belonging to a household in the middle relative to poorest wealth index, and age 30 and above years relative to 25-29 years were associated with higher likelihood of receiving optimal doses of IPTp-SP. In East-Central Uganda, uptake of optimal doses of IPTp-SP is very low. Improving institutional delivery and household wealth, involving religious leaders in programmes to improve uptake of IPTp-SP, and strengthening IPTp-SP activities at lower level health centers may improve uptake of IPTp-SP in the East-Central Uganda.
Sections du résumé
BACKGROUND
BACKGROUND
In 2012, the World Health Organization recommended that pregnant women in malaria-endemic countries complete at least three (optimal) doses of intermittent preventive treatment (IPTp) using sulfadoxine-pyrimethamine (SP) to prevent malaria and related adverse events during pregnancy. Uganda adopted this recommendation, but uptake remains low in East-Central and information to explain this low uptake remains scanty. This analysis determined correlates of uptake of optimal doses of IPTp-SP in East-Central Uganda.
METHODS
METHODS
This was a secondary analysis of the 2016 Uganda Demographic Health Survey data on 579 women (15-49 years) who attended at least one antenatal care (ANC) visit and had a live birth within 2 years preceding the survey. Uptake of IPTp-SP was defined as optimal if a woman received at least three doses; partial if they received 1-2 doses or none if they received no dose. Multivariate analysis using multinomial logistic regression was used to determine correlates of IPTp-SP uptake.
RESULTS
RESULTS
Overall, 22.3% of women received optimal doses of IPTp-SP, 48.2% partial and 29.5% none. Attending ANC at a lower-level health centre relative to a hospital was associated with reduced likelihood of receiving optimal doses of IPTp-SP. Belonging to other religious faiths relative to Catholic, belonging to a household in the middle relative to poorest wealth index, and age 30 and above years relative to 25-29 years were associated with higher likelihood of receiving optimal doses of IPTp-SP.
CONCLUSIONS
CONCLUSIONS
In East-Central Uganda, uptake of optimal doses of IPTp-SP is very low. Improving institutional delivery and household wealth, involving religious leaders in programmes to improve uptake of IPTp-SP, and strengthening IPTp-SP activities at lower level health centers may improve uptake of IPTp-SP in the East-Central Uganda.
Identifiants
pubmed: 32295601
doi: 10.1186/s12936-020-03230-8
pii: 10.1186/s12936-020-03230-8
pmc: PMC7161174
doi:
Substances chimiques
Antimalarials
0
Drug Combinations
0
fanasil, pyrimethamine drug combination
37338-39-9
Sulfadoxine
88463U4SM5
Pyrimethamine
Z3614QOX8W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Références
BMC Pregnancy Childbirth. 2018 Apr 20;18(1):108
pubmed: 29678150
Health Policy Plan. 2013 Mar;28(2):176-84
pubmed: 22522771
Clin Infect Dis. 2011 Aug 1;53(3):215-23
pubmed: 21765069
Lancet Infect Dis. 2011 Mar;11(3):190-207
pubmed: 21273130
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
Lancet. 2016 Feb 6;387(10018):587-603
pubmed: 26794078
Trop Med Infect Dis. 2018 Feb 11;3(1):
pubmed: 30274416
Malar J. 2019 Nov 21;18(1):372
pubmed: 31752868
Malar J. 2016 Jul 04;15(1):341
pubmed: 27377538
Trans R Soc Trop Med Hyg. 2010 Aug;104(8):536-40
pubmed: 20227739
JAMA. 2013 Feb 13;309(6):594-604
pubmed: 23403684
Pan Afr Med J. 2019 Jan 25;32(Suppl 1):13
pubmed: 30949287
Pan Afr Med J. 2017 Oct 10;28:122
pubmed: 29515740
PLoS Med. 2008 Feb;5(2):e44
pubmed: 18288887
J Public Health (Oxf). 2016 Dec 02;38(4):e545-e553
pubmed: 28158717
Malar J. 2016 Jan 07;15:14
pubmed: 26738483
J Infect Dis. 2013 Sep;208(6):907-16
pubmed: 23801600
Lancet Infect Dis. 2013 Dec;13(12):1029-42
pubmed: 24054085
Trans R Soc Trop Med Hyg. 2007 Oct;101(10):980-9
pubmed: 17658564
PLoS One. 2019 Jan 24;14(1):e0203740
pubmed: 30677039
Acta Trop. 2012 Mar;121(3):184-95
pubmed: 21420377
Reprod Health. 2012 Aug 13;9:12
pubmed: 22889320
Malar J. 2016 Nov 4;15(1):530
pubmed: 27809918
BMC Public Health. 2015 Jun 07;15:540
pubmed: 26049737
Malar J. 2014 Jan 14;13:22
pubmed: 24423279
Lancet Glob Health. 2016 Nov;4(11):e845-e855
pubmed: 27670090
Malar Res Treat. 2017;2017:9761289
pubmed: 28465859
Glob Health Sci Pract. 2018 Oct 4;6(3):500-514
pubmed: 30287529
Int J Epidemiol. 2010 Apr;39 Suppl 1:i88-101
pubmed: 20348132
Trop Med Infect Dis. 2019 Feb 07;4(1):
pubmed: 30736456
Trop Med Int Health. 2005 Nov;10(11):1134-40
pubmed: 16262738
Malar J. 2012 Sep 07;11:317
pubmed: 22958539
Malar J. 2017 Mar 27;16(1):132
pubmed: 28347311